Experimental asthma drug briquilimab fails to reach Late-Stage testing
NCT ID NCT06592768
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 1 trial tested a single dose of briquilimab in 17 adults with mild-to-moderate allergic asthma to see if it was safe and could reduce asthma attacks triggered by allergens. The study was terminated early, meaning it did not continue as planned. The main goal was to check for side effects and measure lung function after an allergen challenge.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
briquilimab (also called JSP191)
What this could lead to
If successful, this could point toward a new treatment option for allergic asthma by targeting the underlying immune response.
What could go wrong
This was a very early, small Phase 1 trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
McMaster University
Hamilton, Ontario, L8N 3Z5, Canada
-
University of Alberta
Edmonton, Alberta, T6G 2R3, Canada
-
University of British Columbia
Vancouver, British Columbia, V6T 1Z4, Canada
-
University of Calgary
Calgary, Alberta, T2N 1N4, Canada
-
University of Laval
Québec, Quebec, G1V 0A6, Canada
-
University of Saskatchewan
Saskatoon, Saskatchewan, S7N 5A2, Canada